

Paradigm Biopharmaceuticals Ltd

20:39 16 Apr 2019

Paradigm Biopharmaceuticals secures \$61.3 million in first stage of raising

Paradigm Biopharmaceuticals Ltd (ASX:PAR) has secured \$61.3 million in funding from the institutional component of its rights issue and placement priced at \$1.50.

An additional \$16.6 million is expected to be raised through the retail component of the rights issue, which will open next Wednesday 24 April 2019.

This will take the total capital raising to \$77.9 million as outlined earlier to the market on Monday.

READ: Paradigm Biopharmaceuticals raising \$77.9 million to fund its pivotal phase 3 OA trial

Paradigm's managing director Paul Rennie said: "On behalf of the board we delighted with the overwhelmingly positive response to the release of the osteoarthritis phase 2B secondary endpoint data (on 15 April) and this capital raise.

"The board believes that Paradigm has now secured funding for purposes including the conclusion of our pivotal phase 3 clinical trials for OA and MPS.

New international investors on board

"I take this opportunity to welcome new institutions from the UK, USA, Asia and Australia to the register and to thank our existing shareholders for their ongoing support.

"From a clinical perspective I note the significance of the indicative regression of disease demonstrated by our secondary endpoint data.

"With this combination of funding and compelling clinical data the company is well placed to progress its clinical program whilst pursuing potential commercial transactions."

READ: Paradigm Biopharmaceuticals phase 2b trial achieves key endpoints in OA of the knee


On Monday this week, the company also revealed that it had successfully achieved the secondary endpoints of improved knee function and pain reduction for its phase 2b trial in OA of the knee.

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Price: 1.595

Market Cap: \$315.51 m

1 Year Share Price Graph



April 2019 October 2019 March 2020

Share Information

Code: PAR

Listing: ASX

52 week	High	Low
	4.5	1.08

Sector: Pharma & Biotech

Website: www.paradigmbiopharma.com

Company Synopsis:

Paradigm Biopharmaceuticals Ltd (ASX:PAR) is listed on the Australian Securities Exchange.

action@proactiveinvestors.com

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Paradigm Biopharmaceuticals Ltd named herein, including the promotion by the Company of Paradigm Biopharmaceuticals Ltd in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount

up	to	Twenty	Five	Thousand	dollars	(\$25,000).
----	----	--------	------	----------	---------	-------------